New therapies for lymphoid neoplasms

Jasmine Zain, Yukiko Kitagawa, Matko Kalac, Luca Paoluzzi, Owen A. O’Connor

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The lymphoid neoplasms represent some of the most heterogeneous and diverse malignancies known to medicine. The spectrum of clinical diseases ranges from rapidly growing diseases like Burkitt and lymphoblastic lymphoma to some of the slowest and most indolent cancers known to science, like small lymphocytic lymphoma and follicular lymphoma. This diversity in clinical behavior reflects the molecular heterogeneity that often defines these complex neoplasms which, based on the World Health Organization (WHO) classification, can be subdivided into at least 40 different subtypes.1 Important advances in immunohistochemistry and cytogenetics, coupled with our historical skills in basic morphology, have now allowed the delineation of each non-Hodgkin lymphoma (NHL) subtype as a distinct clinical entity - each with its own unique clinical behavior and treatment paradigms. Recent advances in gene expression profiling (GEP) have led to an entirely new way to think about lymphoma classification based on individual gene clusters that correlate with prognosis and clinical behavior. These types of classification models offer an opportunity to think about designing rational and specific therapeutic regimens targeted against the unique biological basis of the disease. Chapter 84 provides a more extensive update on gene expression profiling of lymphomas.

Original languageEnglish (US)
Title of host publicationThe Lymphoid Neoplasms 3ed
PublisherCRC Press
Pages1481-1499
Number of pages19
ISBN (Electronic)9781444113228
ISBN (Print)9780340809471
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Gene Expression Profiling
Lymphoma
Neoplasms
Follicular Lymphoma
Burkitt Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Multigene Family
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cytogenetics
Non-Hodgkin's Lymphoma
Immunohistochemistry
Medicine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zain, J., Kitagawa, Y., Kalac, M., Paoluzzi, L., & O’Connor, O. A. (2010). New therapies for lymphoid neoplasms. In The Lymphoid Neoplasms 3ed (pp. 1481-1499). CRC Press. https://doi.org/10.1201/b13424

New therapies for lymphoid neoplasms. / Zain, Jasmine; Kitagawa, Yukiko; Kalac, Matko; Paoluzzi, Luca; O’Connor, Owen A.

The Lymphoid Neoplasms 3ed. CRC Press, 2010. p. 1481-1499.

Research output: Chapter in Book/Report/Conference proceedingChapter

Zain, J, Kitagawa, Y, Kalac, M, Paoluzzi, L & O’Connor, OA 2010, New therapies for lymphoid neoplasms. in The Lymphoid Neoplasms 3ed. CRC Press, pp. 1481-1499. https://doi.org/10.1201/b13424
Zain J, Kitagawa Y, Kalac M, Paoluzzi L, O’Connor OA. New therapies for lymphoid neoplasms. In The Lymphoid Neoplasms 3ed. CRC Press. 2010. p. 1481-1499 https://doi.org/10.1201/b13424
Zain, Jasmine ; Kitagawa, Yukiko ; Kalac, Matko ; Paoluzzi, Luca ; O’Connor, Owen A. / New therapies for lymphoid neoplasms. The Lymphoid Neoplasms 3ed. CRC Press, 2010. pp. 1481-1499
@inbook{be491a1baa3a4336ad3c47ffbc7fb44e,
title = "New therapies for lymphoid neoplasms",
abstract = "The lymphoid neoplasms represent some of the most heterogeneous and diverse malignancies known to medicine. The spectrum of clinical diseases ranges from rapidly growing diseases like Burkitt and lymphoblastic lymphoma to some of the slowest and most indolent cancers known to science, like small lymphocytic lymphoma and follicular lymphoma. This diversity in clinical behavior reflects the molecular heterogeneity that often defines these complex neoplasms which, based on the World Health Organization (WHO) classification, can be subdivided into at least 40 different subtypes.1 Important advances in immunohistochemistry and cytogenetics, coupled with our historical skills in basic morphology, have now allowed the delineation of each non-Hodgkin lymphoma (NHL) subtype as a distinct clinical entity - each with its own unique clinical behavior and treatment paradigms. Recent advances in gene expression profiling (GEP) have led to an entirely new way to think about lymphoma classification based on individual gene clusters that correlate with prognosis and clinical behavior. These types of classification models offer an opportunity to think about designing rational and specific therapeutic regimens targeted against the unique biological basis of the disease. Chapter 84 provides a more extensive update on gene expression profiling of lymphomas.",
author = "Jasmine Zain and Yukiko Kitagawa and Matko Kalac and Luca Paoluzzi and O’Connor, {Owen A.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1201/b13424",
language = "English (US)",
isbn = "9780340809471",
pages = "1481--1499",
booktitle = "The Lymphoid Neoplasms 3ed",
publisher = "CRC Press",

}

TY - CHAP

T1 - New therapies for lymphoid neoplasms

AU - Zain, Jasmine

AU - Kitagawa, Yukiko

AU - Kalac, Matko

AU - Paoluzzi, Luca

AU - O’Connor, Owen A.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The lymphoid neoplasms represent some of the most heterogeneous and diverse malignancies known to medicine. The spectrum of clinical diseases ranges from rapidly growing diseases like Burkitt and lymphoblastic lymphoma to some of the slowest and most indolent cancers known to science, like small lymphocytic lymphoma and follicular lymphoma. This diversity in clinical behavior reflects the molecular heterogeneity that often defines these complex neoplasms which, based on the World Health Organization (WHO) classification, can be subdivided into at least 40 different subtypes.1 Important advances in immunohistochemistry and cytogenetics, coupled with our historical skills in basic morphology, have now allowed the delineation of each non-Hodgkin lymphoma (NHL) subtype as a distinct clinical entity - each with its own unique clinical behavior and treatment paradigms. Recent advances in gene expression profiling (GEP) have led to an entirely new way to think about lymphoma classification based on individual gene clusters that correlate with prognosis and clinical behavior. These types of classification models offer an opportunity to think about designing rational and specific therapeutic regimens targeted against the unique biological basis of the disease. Chapter 84 provides a more extensive update on gene expression profiling of lymphomas.

AB - The lymphoid neoplasms represent some of the most heterogeneous and diverse malignancies known to medicine. The spectrum of clinical diseases ranges from rapidly growing diseases like Burkitt and lymphoblastic lymphoma to some of the slowest and most indolent cancers known to science, like small lymphocytic lymphoma and follicular lymphoma. This diversity in clinical behavior reflects the molecular heterogeneity that often defines these complex neoplasms which, based on the World Health Organization (WHO) classification, can be subdivided into at least 40 different subtypes.1 Important advances in immunohistochemistry and cytogenetics, coupled with our historical skills in basic morphology, have now allowed the delineation of each non-Hodgkin lymphoma (NHL) subtype as a distinct clinical entity - each with its own unique clinical behavior and treatment paradigms. Recent advances in gene expression profiling (GEP) have led to an entirely new way to think about lymphoma classification based on individual gene clusters that correlate with prognosis and clinical behavior. These types of classification models offer an opportunity to think about designing rational and specific therapeutic regimens targeted against the unique biological basis of the disease. Chapter 84 provides a more extensive update on gene expression profiling of lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=85056030354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056030354&partnerID=8YFLogxK

U2 - 10.1201/b13424

DO - 10.1201/b13424

M3 - Chapter

AN - SCOPUS:85056030354

SN - 9780340809471

SP - 1481

EP - 1499

BT - The Lymphoid Neoplasms 3ed

PB - CRC Press

ER -